What makes TGR-1202 different from other PI3K inhibitors?

Owen O’Connor, MD, PhD from Columbia University Medical Center, New York, NY discusses his colleague Dr George Deng’s investigation into the PI3 kinases, with the aim of understanding why TGR-1202 is different from idelalisib and duvelisib. His work has reinforced the knowledge of TGR-1202’s chemical structure and the effect it has on protein translation, specifically Myc protein. Prof. O’Connor also discusses the Phase II UNITY trial (NCT02793583) that aims to assess the efficacy and safety of ublituximab + TGR-1202 and TGR-1202 monotherapy in patients previously treated for diffuse large B-cell lymphoma (DLBCL). Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

Share this video